EFFECT OF SUN EXPOSURE DURATION ON CYCLOOXYGENASE-2 EXPRESSION IN THE CONJUNCTIVA.
Conjunctiva
Cyclooxygenase 2
Pterygium
Sunlight – adverse effects
Journal
Acta clinica Croatica
ISSN: 1333-9451
Titre abrégé: Acta Clin Croat
Pays: Croatia
ID NLM: 9425483
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
16
7
2020
Statut:
ppublish
Résumé
Pterygium is a multifactorial proliferative pathologic change of bulbar conjunctiva. The purpose of this study was to determine the effect of the duration of exposure to solar radiation (expressed in years) on the incidence of positive cyclooxygenase-2 (COX-2) finding in conjunctival tissue in two groups of patients. Group 1 consisted of 68 patients with primary pterygium having undergone conjunctival autograft transplantation. Group 2 consisted of 43 patients with morphologically unchanged conjunctivae that were harvested during cataract surgery. All 111 specimens were submitted to immunohistochemical staining for monoclonal COX-2 antibody (1:100; M361701 MO A-HU, Dako, Santa Clara, California, USA). The immunostaining intensity in the surface epithelium was scored using the following grading system: 0 no immunostaining; + weak immunostaining (few cells being positive focally or scattered); ++ medium immunostaining; and +++ strong immunostaining (diffuse staining throughout the tissue). The analysis of COX-2 activity yielded 29 (42.6%) positive findings in group 1 and 27 (62.8%) positive findings in group 2. Group 2 consisted of statistically significantly older individuals with a history of considerably longer sun exposure. Statistical analysis proved the duration of exposure to solar radiation to be the most important factor in positive COX-2 findings.
Identifiants
pubmed: 32595249
doi: 10.20471/acc.2019.58.04.11
pii: acc-58-639
pmc: PMC7314286
doi:
Substances chimiques
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
639-646Références
Mol Vis. 2011;17:3468-80
pubmed: 22219642
Mol Carcinog. 1999 Aug;25(4):231-40
pubmed: 10449029
Ocul Surf. 2008 Jan;6(1):24-43
pubmed: 18264653
Coll Antropol. 2007 Jan;31 Suppl 1:45-7
pubmed: 17469749
FASEB J. 2004 Feb;18(2):300-10
pubmed: 14769824
BMJ Open. 2013 Nov 19;3(11):e003787
pubmed: 24253031
Coll Antropol. 2007 Jan;31 Suppl 1:39-41
pubmed: 17469747
Br J Ophthalmol. 1979 Feb;63(2):102-9
pubmed: 427069
Acta Histochem. 1996 Apr;98(2):195-201
pubmed: 8739304
Cell. 1995 Nov 3;83(3):493-501
pubmed: 8521479
J Clin Periodontol. 1997 May;24(5):297-305
pubmed: 9178108
Mol Vis. 2009;15:458-63
pubmed: 19247455
Int Ophthalmol Clin. 2009 Winter;49(1):21-30
pubmed: 19125061
Mol Vis. 2007 Apr 27;13:635-8
pubmed: 17515883
Eye (Lond). 2009 May;23(5):1125-9
pubmed: 18600244
Indian J Ophthalmol. 2009 May-Jun;57(3):203-6
pubmed: 19384014
Mol Vis. 2005 Jan 25;11:71-5
pubmed: 15692461
Br J Ophthalmol. 2003 Jul;87(7):864-6
pubmed: 12812887
Mol Carcinog. 2007 Aug;46(8):692-8
pubmed: 17443745
Am J Ophthalmol. 1999 Sep;128(3):280-7
pubmed: 10511020
Subcell Biochem. 2007;42:3-27
pubmed: 17612044
Oncogene. 1999 Dec 20;18(55):7908-16
pubmed: 10630643
J Environ Pathol Toxicol Oncol. 2002;21(2):183-91
pubmed: 12086405
Indian J Ophthalmol. 2008 Jul-Aug;56(4):279-83
pubmed: 18579985
Br J Dermatol. 1999 Jun;140(6):1017-22
pubmed: 10354065
Clin Exp Ophthalmol. 2007 Dec;35(9):828-33
pubmed: 18173411